1015. Real World Use of Dalbavancin and Oritavancin for Optimized Outpatient Antimicrobial Therapy in Patients Inappropriate for Standard Therapy

BACKGROUND: Dalbavancin and oritavancin are long acting lipoglycopeptide antibiotics (LaLGP) approved for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms. These antibiotics have shown promise in treatment of non-FDA approved gram...

Descripción completa

Detalles Bibliográficos
Autores principales: Weichman, Brittani, Bushman, Amanda, Aarhus, Angela, Terrero Salcedo, David A, Drake, Ty C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751981/
http://dx.doi.org/10.1093/ofid/ofac492.856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751981/
http://dx.doi.org/10.1093/ofid/ofac492.856

Ejemplares similares